Bharat Parenterals Ltd.

As of June 30, 2026, Bharat Parenterals Ltd. carries a market capitalization of 9.65B, placing it among publicly traded companies globally. Its enterprise value stands at 9.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bharat Parenterals Ltd. has 6.89M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Bharat Parenterals Ltd. trades at an EV/EBITDA multiple of 91.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.65B versus a market cap of 9.65B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 8.11M in revenue per employee across its workforce of 398.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bharat Parenterals Ltd. recorded 45.34M in income tax expense. The company reported a pretax loss of -254.59M and -163.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bharat Parenterals Ltd.'s stock has gained approximately 40.16% over the past 52 weeks. The 50-day moving average sits at 1,614.53, while the 200-day moving average is 1,319.89.

Over the twelve months ended June 30, 2026, Bharat Parenterals Ltd. generated 3.23B in revenue and converted that into -163.11M in net income, yielding earnings per share of -46.42. EBITDA reached 105.73M, while operating income came in at -237.60M.

Over the twelve months ended June 30, 2026, Bharat Parenterals Ltd. posted a gross margin of 49.47, reflecting its pricing power and cost economics. The operating margin of -7.35 and net profit margin of -5.05 provide insight into operational efficiency.